Regulation of immunity and inflammation by intravenous immunoglobulin: Relevance to solid organ transplantation

Expert Review of Clinical Immunology

Volumn 7, Issue 3, 2011, Pages 341-348

  Jordan, Stanley C ^a   Toyoda, Mieko ^a   Vo, Ashley A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

alloimmunity; antibody mediated rejection; cell mediated immunity; complement; desensitization; Fcg receptor IIB; inflammation; IVIg

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIBODY; CD40 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN; INTERLEUKIN 6;

ALLOGRAFT; CELLULAR IMMUNITY; CYTOLYSIS; DENDRITIC CELL; IMMUNE INJURY; IMMUNE RESPONSE; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 79957508762     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.10     Document Type: Review

References (49)

1. Nimmerjahn F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008). (Pubitemid 351600384)
2. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun. Rev. 5, 465-470 (2006).
3. Tha-In T, Bayry J, Metsellar H, Kaveri S, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29, 608-615 (2008).
4. Jordan SC, Toyoda M, Vo A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88, 1-6 (2009).
5. Elibl M. History of immunoglobulin replacement. Immunol. Allergy Clin. N. Am. 28, 737-764 (2008).
6. Durandy A, Kaveri S, Kujipers T et al. Intravenous immunoglobulins- understanding properties and mechanisms. Clin. Exp. Immunol. 158, 2-13 (2009).
7. Shehata N, Palda V, Meyer R et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus. Med. Rev. 24, 7-27 (2010).
8. Nahirniak S, Hume H. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus. Med. Rev. 24, 1-6 (2010).
9. Jordan SC, Toyoda M, Kahwaji J, Vo A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am. J. Transplant. 11(2), 196-202 (2011).
10. Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66(6), 800-805 (1998).
11. Casadei DH, del C Rial M, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71, 53-58 (2001). (Pubitemid 32105778)
12. Jordan SC, Reinsmoen N, Peng A et al. Advances in diagnosis and managing antibody-mediated rejection. Pediatr. Nephrology 10, 2035-2048 (2010).
13. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 18(4), 1046-1056 (2007). (Pubitemid 46536891)
14. Arumugam TV, Woodruff TM, Lathia JD et al. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 158(3) 1074-1089 (2008).
15. Basta M. Ambivalent effect of immunoglobulin on the complement system: activation versus inhibition. Mol. Immunol. 45, 4073-4079 (2008).
16. Thurman J. Triggers of inflammation after renal ischemia/reperfusion injury. Clin. Immunol. 123, 7-13 (2007). (Pubitemid 46401502)
17. Arumugam TV, Tang SC, Lathia JD et al. Intravenous immunoglobulin (IVIg) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl Acad. Sci. USA 104, 14104-14109 (2007). (Pubitemid 350003342)
18. Arumugam TV, Selvaraj PK, Woodruff TM, Mattson MP. Targeting ischemic brain injury with intravenous immunoglobulin. Expert Opin. Ther. Targets 12, 19-29 (2008). (Pubitemid 351247159)
19. Basta M, Van Goor F, Luccioli S et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat. Med. 9, 431-438 (2003). (Pubitemid 36460077)
20. Sameulsson A, Towers TL, Ravetch JV. Anti-inflamatory activity of IVIg mediated through the inhibitory Fc receptor. Science 29, 484-486 (2001). (Pubitemid 32097072)
21. Smith K, Clatworthy M. FcgRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328-343 (2010).
22. Kaneko Y, Nimmerjahn F, Madaio M, Ravetch J. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789-797 (2006).
23. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIg anti-inflammatory activity with a recombinant IgG Fc. Science 320(5874), 373-376 (2008). (Pubitemid 351555659)
24. Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006). (Pubitemid 44201145)
25. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIg. Proc. Natl Acad. Sci. USA 105(50), 19571-19578 (2008).
26. Kaveri S, Lacroix-Desmazes S, Bayry J. The anti inflammatory IgG. N. Engl. J. Med. 359, 307-309 (2008).
27. Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and a 2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc. Natl Acad. Sci. USA 106(9), E24 (2009).
28. Aubin E, Lemieux R, Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 115, 1727 (2010).
29. Crow A, Brinc D, Lazarus A. New insights into the mechanisms of action of IVIg: the role of dendritic cells. J. Thromb Haemost. 7, 245-248 (2009).
30. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101, 758-765 (2003). (Pubitemid 36077604)
31. Tha-In T, Metselaar HJ, Tilanus HW et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 81, 1725-1734 (2006). (Pubitemid 43948307)
32. Smed-Sörensen A, Moll M, Cheng TY et al. IgG regulates the CD1 expression profile and lipid antigen presenting function in human dendritic cells via FcgRIIa. Blood 111, 5037-5046 (2008).
33. Chong B, Chong J. IVIg inhibitory activity: APC is the key. Blood 115, 1663-1664 (2010).
34. Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 174(9), 5837-5845 (2005). (Pubitemid 40593229)
35. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am. J. Transplant. 3, 156-166 (2003). (Pubitemid 36323113)
36. Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 112, 2031-2039 (2005). (Pubitemid 41377423)
37. Turhan A, Jenab P, Bruhns P, Ravetch J, Coller B, Frenette P. Intravenous gammaglobulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 103, 2397-2400 (2004). (Pubitemid 38326264)
38. Séité JF, Renaudineau Y, Youinou P, Maseed RA, Hillion S. IVIg modulates BCR-signaling through CD22 and promotes apoptosis in mature human B-lymphocytes. Blood 116(10) 1698-1704 (2010).
39. Proulx D, Aubin E, Lemieux R, Bazin R. Inhibition of B-cell mediated antigen presentation by intravenous immunoglobulin. Clin. Immunol. 135(3), 422-429 (2010).
40. Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gammaglobulin. Transplant. Immunol. 2(4), 337-341 (1994).
41. Kessel A, Ammuri H, Peri R et al. Intravenous immunoglobulin therapy affects T-regulatory cells by increasing their suppressive function. J. Immunol. 179, 5571-5575 (2007).
42. +, FoxP3+ T-cells. Transplantation 89, 1446-1452 (2010).
43. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide Tregitopes. Blood 112(8), 3303-3311 (2008).
44. Maddur M, Shivashankar O, Hegde P et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T-cells. J. Clin. Immunol. 30(Suppl. 1), S4-S8 (2010).
45. Li N, Zhao M, Hilario-Vargas J et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115, 3440-3450 (2005). (Pubitemid 43121832)
46. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol. 15, 3256-3262 (2004). (Pubitemid 39578859)
47. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. Transplantation 70, 887-895 (2000).
48. Jordan SC, Pescovits M. Presensitization: the problem and its management. Clin. J. Am. Soc. Nephrol. 1, 421-432 (2006).
49. Vo, A, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242-251 (2008). (Pubitemid 352008439)